Under-the-Skin Tepezza Comparable to Infused Version in Key Study, Amgen Says
Amgen announced that its subcutaneous on‑body injector version of Tepezza, called Tepezza OBI, met both primary and key secondary endpoints in a late‑stage trial, showing 77% of patients achieved a meaningful reduction in eye bulging. The efficacy was comparable to the existing intravenous formulation, with a 3.17 mm average proptosis reduction and a safety profile consistent with the marketed drug. The results could revive growth for the $2 billion‑a‑year franchise, which has stalled due to infusion‑center logistics. Analysts see the convenient delivery method as a way to expand the thyroid eye disease market.
VDyne Secures FDA Nod to Start Pivotal Trial for Tricuspid Valve
VDyne received FDA approval for an investigational device exemption to launch its pivotal TRIVITA trial of a transcatheter tricuspid valve replacement system. The study will assess safety and efficacy in patients with severe symptomatic tricuspid regurgitation, a condition affecting roughly...
FDA Public Meeting: FDA-Led Patient-Focused Drug Development Meeting for Nonhealing Chronic Wounds - 08/25/2026
On August 25, 2026 the FDA will host a hybrid Patient‑Focused Drug Development meeting dedicated to non‑healing chronic wounds. The public session runs from 10 a.m. to 4:30 p.m. ET and combines a virtual webcast with an in‑person gathering at the White Oak Campus....
Proposed FDA Budget Sets Makary up to Boost US Biotech
The White House’s FY budget proposes a sizable increase for the FDA, positioning Dr. Robert Makary to spearhead regulatory reforms aimed at accelerating U.S. biotech development. The plan includes policy changes that would shorten clinical‑trial timelines, lower fees for early‑stage...
Can Medicinal Cannabis Help Kids’ Autism, ADHD or Tourette’s? Here’s What We Know so Far
Interest in medicinal cannabis for children with autism, ADHD and Tourette's has grown, prompting the Australian Therapeutic Goods Administration to confirm that doctors are prescribing it for these conditions. While parents hope it could reduce reliance on stimulants, antidepressants and...
Global Cohort Data Bolster Confidence in Dolutegravir for Pediatric HIV Care
A new analysis presented at CROI 2026 used International Epidemiology Databases to Evaluate AIDS (IeDEA) data from Africa, Asia‑Pacific, and Latin America, covering over 90% of the world’s children with HIV. The study found that dolutegravir initiates modest early weight gain...
Startup Approved to Let AI System Prescribe Psychiatric Medication
Legion Health, a San Francisco startup, received Utah regulatory approval to let its AI chatbot renew psychiatric prescriptions for a limited set of antidepressants such as Prozac and Zoloft. The system can only prescribe drugs previously authorized by a human...
BIO’s Comments for USTR Report Highlight Global Threats to Intellectual Property
The Biotechnology Innovation Organization (BIO) submitted comments to the USTR’s 2026 Special 301 Report urging stronger global enforcement of intellectual‑property (IP) rights for biotech. BIO argues that weak IP protections in markets such as Colombia, Russia and Brazil create barriers...
Other News to Note for April 6, 2026
Jiangsu and Shanghai Hengrui have patented selective Nav1.8 sodium‑channel blockers that show pre‑clinical analgesic efficacy with fewer side effects. New hematopoietic stem‑cell research links chronic inflammation to early leukemic transformation, identifying inflammatory pathways as therapeutic targets. Infinimmune presented pre‑clinical data...
Biopharma Financings Nearly Double Vs. 2025 to $25.1B
Biopharma financing nearly doubled year‑over‑year, reaching about $25.1 billion, fueling a wave of early‑stage research. Jiangsu and Shanghai Hengrui patented novel Nav1.8 sodium‑channel blockers aimed at chronic pain relief. New hematopoietic stem‑cell studies link inflammation to the earliest stages of leukemia,...
Regulatory Actions for April 6, 2026
BioWorld’s April 6, 2026 regulatory snapshot aggregates the day’s key FDA and global health authority actions across biopharma, medical technology, and diagnostics. The page links to data snapshots, special reports, infographics and trend analyses covering topics such as mRNA vaccine research, GLP‑1...
Over-the-Counter Medication Abortion? These Researchers Say It Would Be Safe
Researchers at UCSF surveyed 168 patients about a prototype over‑the‑counter medication abortion kit, finding 88% concordance between self‑assessment and clinician eligibility. The study, published in JAMA Internal Medicine, suggests patients can reliably determine suitability for mifepristone‑misoprostol regimens without a prescriber....
Amgen Seeks to Buoy Tepezza with Injectable Data in Face of Incoming Competition
Amgen announced that its injectable formulation of Tepezza achieved its primary endpoint in a Phase 3 trial for thyroid eye disease (TED). The data suggest the drug can be administered subcutaneously, offering a more convenient alternative to the current intravenous...
Machine Learning and Single-Cell Technology Combined to Drive High-Performance Cell Line Development
OneCyte and Kemp Proteins have formed a strategic partnership that fuses OneCyte’s high‑throughput single‑cell cloning platform with Kemp’s machine‑learning‑driven protein design system, PROTiQ. The combined workflow uses in‑silico sequence evaluation to flag developability risks, then rapidly screens thousands of clones...
Anthropic Pays $400M for Biotech; Praxis Epilepsy Drug Hits in Phase 1/2 Trial
San Francisco AI firm Anthropic announced a $400 million acquisition of stealth biotech Coefficient Bio, signaling its push into drug discovery. The purchase aims to integrate Anthropic’s large‑language‑model capabilities with biotech research pipelines. In parallel, Praxis Therapeutics disclosed encouraging Phase 1/2 data...
Takeda Ends Partnership with Denali Amid Restructuring
Takeda announced the termination of its eight‑year partnership with Denali Therapeutics, returning full rights to the experimental drug DNL593 ahead of its upcoming Phase I trial. The move is part of Takeda's broader restructuring aimed at streamlining its portfolio and...
African Patients and Trialists Largely Left Out of CV Research
A new study reveals that African populations are dramatically underrepresented in cardiovascular clinical trials, with less than 4 % of 2,472 randomized controlled trials (RCTs) conducted exclusively in Africa and only 0.6 % appearing in top cardiology journals. Lead author Bamba Gaye...
STAT+: Pharmalittle: We’re Reading About an FDA Delay Forcing a Biotech to Close, a Neurocrine Deal, and More
In February, Kezar Life Sciences secured an FDA agreement for a clinical trial on autoimmune hepatitis, but the meeting was cancelled four months late, prompting the biotech to begin winding down. Meanwhile, U.S. physicians are increasingly prescribing oral GLP‑1 weight‑loss...
Rethinking eCOA: Why Earlier Input by Data Managers Is Needed
Electronic clinical outcome assessment (eCOA) is a mature technology, yet its adoption lags behind other digital trial tools. The traditional siloed approach forces data managers to engage only after data collection, inflating costs and extending timelines. Involving data managers early...
Engineered Antibodies Pry Apart The Most Difficult Viruses
Researchers have engineered a bifunctional antibody fragment that simultaneously blocks Marburg virus attachment and neutralizes the exposed receptor‑binding site after the virus undergoes its conformational change. By mimicking the host cell receptor, the antibody tightly binds the viral protein, shutting...
Neurocrine to Acquire Prader-Will Drug in $2.9B Soleno Buyout
Neurocrine Biosciences agreed to acquire Soleno Therapeutics for $2.9 billion, securing the rare‑disease drug Vykat XR. Vykat generated $190 million in 2025 sales, including $92 million in the fourth quarter, but recent safety concerns and a slowdown in new patient starts have clouded its...
‘Over and Above’ Responses Seen with Envudeucitinib for Plaque Psoriasis
Phase 3 ONWARD 1 and ONWARD 2 trials showed that envudeucitinib, an oral next‑generation TYK2 inhibitor, produced rapid and deep skin clearance in moderate‑to‑severe plaque psoriasis. At week 16, 76.5% and 70.4% of patients achieved PASI‑75, with rates climbing above 78% by week 24, and...
CuraTeQ Biologics Gets ‘Positive’ Results in Phase Study of Omalizumab
CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, announced positive top‑line results from its Phase 3 trial of BP11, a biosimilar to omalizumab (Xolair). The study enrolled 608 patients across 80 sites in seven European countries and India, meeting all primary endpoints...
STAT+: Stealth Biotech Stipple Bets on Secretive ADCs
Stealth biotech Stipple is quietly advancing secretive antibody‑drug conjugates (ADCs) as the market races toward targeted cancer therapies. A recent four‑month FDA review delay forced a cash‑strapped small biotech to shut down, underscoring the existential risk of regulatory setbacks for...
Pharma Pipeline Stalls for First Time in Decades: Citeline
The Citeline Pharma R&D report shows the first decline in investigational drug candidates since the mid‑1990s, with the pipeline falling 3.92% to 22,940 assets at the start of 2026. While a methodological tweak may have softened the drop, the contraction...
Media Networks Sydney Pty Limited - 687044 - 09/18/2024
The U.S. Food and Drug Administration issued a closeout letter to Media Networks Sydney Pty Ltd confirming that the company has discontinued its U.S. listings for Mylanta 2go Antacid Double Strength and Microlax Enema after corrective actions. The agency noted that...
AI Is Coming for Superbugs
Antibiotic resistance could cause over 39 million deaths by 2050, with more than 8 million annual fatalities by mid‑century. Traditional drug discovery is slow, expensive, and the pipeline for new antibiotics has been shrinking for decades. Artificial‑intelligence models can screen tens to...
Takeda Breaks Up With Denali, Dumps Dementia Drug
Takeda Pharmaceutical has ended its eight‑year partnership with Denali Therapeutics, returning all rights to the frontotemporal dementia candidate DNL593. The split follows earlier termination of the joint Alzheimer’s program DNL919 and is attributed to strategic considerations rather than safety or...
Novel Approach to Clearing Brain Waste Shows Promise for Alzheimer's
Researchers have identified a novel method to boost the brain’s waste‑disposal system by targeting the DDR2 receptor, a protein previously studied for lung health. In mouse models, blocking DDR2 lowered amyloid‑beta production and enhanced clearance of toxic protein aggregates, leading...
Affinia Therapeutics Receives Approval From Health Canada to Initiate the UPBEAT© Trial, a Phase 1/2 Clinical Trial to Investigate AFTX-201...
Affinia Therapeutics has secured Health Canada approval to launch the UPBEAT© Phase 1/2 trial of its gene‑therapy candidate AFTX‑201 for BAG3‑associated dilated cardiomyopathy. The investigational product delivers a full‑length BAG3 transgene via a proprietary low‑dose AAV capsid, aiming for a one‑time...
Neurocrine Will Pay $2.9B for Soleno and Its Prader-Willi Medicine
Neurocrine BioSciences announced a $2.9 billion acquisition of Soleno Therapeutics, paying $53 per share for the rare‑disease specialist. The deal brings Soleno’s late‑stage Prader‑Willi syndrome therapy into Neurocrine’s growing portfolio. Soleno, a profitable company, adds a commercial platform and additional rare‑disease...
Databricks Launches AiChemy Multi-Agent AI for Drug Discovery
Databricks unveiled AiChemy, a reference architecture for a multi‑agent AI system that merges internal enterprise data with external scientific databases via its Model Context Protocol. The platform leverages Delta Lake, Mosaic AI and Agent Bricks to create domain‑specific skills such...
Neurocrine Expands Into Metabolic Diseases with $2.9 Billion Soleno Buyout
Neurocrine Biosciences announced a $2.9 billion cash acquisition of Soleno Therapeutics, marking its first foray into metabolic diseases. The deal secures Vykat XR, the inaugural FDA‑approved treatment for hyperphagia in Prader‑Willi syndrome, expanding Neurocrine’s rare‑disease portfolio. Soleno shareholders receive $53 per share,...
Stipple Bio Launches with $100M to Find More Precise Targets on Cancer Proteins
Stipple Bio, founded by cancer biologists Aaron Ring and colleagues, announced its launch with a $100 million Series A round. The company’s mission is to pinpoint highly precise binding sites on cancer‑related proteins, steering clear of oversaturated targets like PD‑1×VEGF or HER2....
Parkinson’s Awareness Month 2026: Alpha Synuclein Emerges as Leading Target in Disease Pipeline
During Parkinson’s Awareness Month 2026, GlobalData reports a clear shift in the drug development landscape toward alpha‑synuclein as the top therapeutic target. While 53% of the 64 approved Parkinson’s drugs still focus on dopamine receptors, the pipeline now includes 62...
China's Syneron Raises $150M for Peptides, Adding to Last Year's $100M
Chinese biotech Syneron Bio announced a $150 million Series B financing round, bringing its total capital raised to $250 million after a $100 million round last year. The funds will be allocated to advance its peptide therapeutic platform, a drug...
Novo Nordisk: Downgrading To 'Sell' As GLP-1 Pipeline Faces Many Risks
Novo Nordisk was downgraded from Buy to Sell as its GLP‑1 pipeline encounters multiple headwinds. The CagriSema obesity candidate failed to prove non‑inferior weight loss against Eli Lilly’s tirzepatide in the REDEFINE‑4 trial, dampening pipeline momentum. Meanwhile, the oral Wegovy launch is...
The Antibiotic Trap
India’s antibiotics are cheap, ubiquitous and often sold in half‑doses by street‑side pharmacies to workers who cannot afford missed wages. Weak regulatory oversight, rampant use in livestock and massive pharmaceutical‑plant waste have created a perfect storm for antimicrobial resistance (AMR)....
Perks Persuade Participants
Clinical trial sponsors are shifting from cash and checks to reloadable incentive cards to streamline participant compensation. Reloadable cards function like debit cards, allowing multiple reloads, real‑time tracking, and universal acceptance. InComm InCentives' Participant Perks Card offers a Visa‑branded, white‑label...
Denali Regains Full Rights to Frontotemporal Dementia Therapy as Takeda Exits DNL593 Pact
Denali Therapeutics has regained full rights to its investigational frontotemporal dementia (FTD) therapy DNL593 after Takeda terminated their co‑development agreement for strategic reasons. DNL593 is a progranulin replacement drug that uses Denali’s Protein Transport Vehicle (PTV) platform to cross the...
STAT+: How a Four-Month FDA Delay Forced a Small Biotech Company to Close Its Doors
Kezar Life Sciences, a small biotech developing a treatment for autoimmune hepatitis, saw a critical FDA meeting cancelled four months late, derailing its trial timeline. The delay forced investors to withdraw, prompting the company to lay off most of its...
Is FDA Moving the Goalposts on 483 Responses? What the New Draft Guidance Means for Your Company
The FDA released its first draft guidance outlining how drug, biologic and veterinary manufacturers should respond to Form FDA 483 observations. The document mandates a structured response—including an executive summary, risk assessments, and detailed remediation plans—and requires identification of the...
Toward the Simultaneous Detection of Multiple Diseases with a Highly Cost-Effective Cell-Free DNA Methylome Test
Researchers introduced MethylScan, a low‑cost cell‑free DNA methylome sequencing assay that profiles the entire cfDNA methylome from a single blood draw. In a cohort of 1,061 individuals, the test achieved an AUROC of 0.938 for multicancer detection (63.3% sensitivity at...
Testosterone Isn’t a Magic Cure-All for Middle Age
Social media influencers have promoted testosterone therapy as a cure‑all for perimenopausal women, promising energy, sharper cognition, and a revived libido. Medical experts caution that the only proven benefit is a modest increase in sexual satisfaction for postmenopausal women, and...
Cancer Immunotherapy Works Better Earlier in the Day
Advanced Science News highlighted three breakthrough studies: a fluorescent sensor that provides real‑time detection of E. coli in catheter bags, enabling earlier intervention for urinary tract infections; a systematic analysis of lipid‑nanoparticle components that clarifies how each interacts with cells, paving...
Portugal’s Biotech Industry Is Growing Up
Portugal’s biotech sector is shedding its niche reputation, with turnover among trade‑group members more than tripling between 2016 and 2020 and over half of firms earning the majority of revenue from exports. A multi‑node cluster model spanning Cantanhede, Porto, Braga,...
FDA Reversals in Rare Disease Space Highlight Confusion Around External Controls
In 2024 the FDA signaled support for using natural‑history external controls in rare‑disease gene‑therapy trials, but later reversed that stance for uniQure’s Huntington’s therapy, demanding a sham‑surgery Phase 3 study. The agency’s guidance still encourages innovative designs, yet recent reversals for...
Lean Derisking: Smart Ways to Cross Drug Development’s “Valley of Death”
API’s recent webinar highlighted practical strategies to bridge the drug‑development "valley of death," emphasizing early derisking from discovery through first‑in‑human studies. The panel stressed using AI‑driven in‑silico filters, staged in‑vitro and animal testing, and aligning preclinical models with clinical biomarkers...
Morning Brief Podcast: Pharma's AI Reckoning
The Economic Times podcast examined how artificial intelligence is reshaping pharma, highlighting AlphaFold’s ability to shrink protein‑structure projects from months to weeks and Lupin’s rollout of generative AI across more than 90 data repositories. Guests from PwC India, Dr. Reddy’s and...
Orexin Receptor Antagonists for Major Depressive Disorder: Perspectives From a Systematic Review and Meta-Analysis
A systematic review and meta‑analysis of orexin receptor antagonists (QXR‑ANTs) in adults with major depressive disorder found a modest but statistically significant reduction in overall symptom scores (standardized mean difference –0.16) and a 52% increase in remission rates compared with...